Skip to Content
Merck
All Photos(2)

Key Documents

SAB4500780

Sigma-Aldrich

Anti-EPO-R antibody produced in rabbit

affinity isolated antibody

Synonym(s):

EPO-R, EPOR, Erythropoietin receptor precursor

Sign Into View Organizational & Contract Pricing
All Photos(2)

About This Item

MDL number:
MFCD01092334
UNSPSC Code:
12352203
PubChem Substance ID:
329824642
NACRES:
NA.41

biological source

rabbit

Quality Level

100

conjugate

unconjugated

antibody form

affinity isolated antibody

antibody product type

primary antibodies

clone

polyclonal

form

buffered aqueous solution

mol wt

antigen 55 kDa

species reactivity

mouse, human, rat

concentration

~1 mg/mL

technique(s)

ELISA: 1:5000
immunofluorescence: 1:100-1:500
western blot: 1:500-1:1000

NCBI accession no.

P19235

UniProt accession no.

P19235

shipped in

wet ice

storage temp.

−20°C

target post-translational modification

unmodified

InChI

1S/C40H74O3/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-31-33-35-37-39(41)43-40(42)38-36-34-32-30-28-26-24-22-20-18-16-14-12-10-8-6-4-2/h17-20H,3-16,21-38H2,1-2H3/b19-17-,20-18-

InChI key

QLXNJYBNAORLFC-CLFAGFIQSA-N

Gene Information

human ... EPOR(2057)

General description

Anti-EPO-R Antibody detects endogenous levels of total EPO-R protein.

Immunogen

The antiserum was produced against synthesized peptide derived from human Epo-R.

Immunogen Range: 341-390

Features and Benefits

Evaluate our antibodies with complete peace of mind. If the antibody does not perform in your application, we will issue a full credit or replacement antibody. Learn more.

Physical form

Rabbit IgG in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Not finding the right product?  

Try our Product Selector Tool.

Storage Class Code

10 - Combustible liquids

WGK

nwg

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Estefanía Vázquez-Méndez et al.
Mediators of inflammation, 2020, 8937657-8937657 (2020-03-19)
Chronic kidney disease (CKD) causes anemia by renal damage. In CKD, the kidney is submitted to hypoxia, persistent inflammation, leading to fibrosis and permanent loss of renal function. Human recombinant erythropoietin (rEPO) has been widely used to treat CKD-associated anemia
Fan Yang et al.
Haematologica, 104(10), 1984-1994 (2019-03-02)
Transmembrane protein 30A (Tmem30a) is the β-subunit of P4-ATPases which function as flippase that transports aminophospholipids such as phosphatidylserine from the outer to the inner leaflets of the plasma membrane to maintain asymmetric distribution of phospholipids. It has been documented
Paul E Constanthin et al.
Development (Cambridge, England), 147(19) (2020-08-09)
Erythropoietin (EPO), the hypoxia-inducible hematopoietic hormone, has well-established neuroprotective/neurotrophic roles in the developing central nervous system and the therapeutic potential of EPO has been widely explored in clinical studies for the treatment of perinatal hypoxic brain lesion, as well as
Min-Soo Kwon et al.
Neurological research, 36(3), 215-223 (2014-02-12)
Even though erythropoietin (EPO) is a neurotropic cytokine that is recognized widely for its role in the development, maintenance, protection, and repair of the nervous system, there are few reports concerning EPO-mediated influences on the glial cells in the central
Dirk Rades et al.
Anticancer research, 34(8), 4351-4355 (2014-07-31)
Long-term results of a study investigating potential prognostic factors for treatment outcomes in patients with stage III esophageal cancer are presented. In 64 patients, the impact of tumor cell expression of erythropoietin (EPO) and erythropoietin-receptor (EPO-R) and ten additional factors

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service